Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease

Table 2 Overview of significant group-wise comparison fold changes

Protein	MCI vs. ND	AD vs. ND	Amyloid-positive vs. amyloid-negative	Tau-positive vs. tau-negative
VEGF	n.s.	n.s.	0.9	0.9
sVEGFR-1	n.s.	n.s.	1.1	1.3
MCP-1	n.s.	n.s.	n.s.	1.1
IP-10	n.s.	n.s.	n.s.	1.2
IL-6	n.s.	n.s.	n.s.	n.s.
IL-8	n.s.	n.s.	n.s.	n.s.
SAA	n.s.	n.s.	n.s.	n.s.
CRP	0.6	0.5	0.5	0.7
sICAM-1	n.s.	n.s.	1.1	1.1
sVCAM-1	n.s.	n.s.	1.1	1.2
MIF	n.s.	n.s.	n.s.	1.3
C1q	n.s.	n.s.	n.s.	1.3
C3aDesArg	n.s.	n.s.	n.s.	n.s.
sIL-1RAcP	n.s.	n.s.	1.1	1.1
sTREM2	1.4	1.4	1.4	1.7

Abbreviations: Aβ₄₀ β-Amyloid 1–40, Aβ₄₂ β-Amyloid 1–42, AD Patients with Alzheimer’s disease, CRP C-reactive protein, IL Interleukin, IP-10 Interferon-γ-induced protein 10, MCI Patients with mild cognitive impairment, MCP-1 Monocyte chemoattractant protein 1, MIF Macrophage migration inhibitory factor, ND Nondemented subjects, SAA Serum amyloid A protein, sICAM-1 Soluble intercellular adhesion molecule 1, sIL-1RAcP Soluble inhibition of soluble interleukin-1 receptor accessory protein, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, sVCAM-1 Soluble vascular cell adhesion molecule 1 factor, sVEGFR-1 Soluble vascular endothelial growth factor receptor 1, VEGF Vascular endothelial growth
The table lists only significant comparisons and only fold changes of median values. Insignificant changes are marked as not significant (n.s.). Amyloid pathology was defined by Aβ₄₂/Aβ₄₀ ratio; tau pathology was defined by total-tau. For detailed descriptions of median values, SDs, and ranges, see Additional file 2, page 8 and following)

ISSN: 1758-9193